Chemours falls 2.7% as law firms announce securities class action suits tied to Opteon demand

What happened

Chemours (CC) fell 2.7% on October 14, 2026, in an ordinary session; multiple law firms announced securities class action lawsuits tied to weaker-than-expected demand for Opteon refrigerants and set a December 7, 2026, deadline for lead plaintiff motions. The filings cover investors who bought Chemours securities between February 20, 2026, and August 4, 2026, and several notices cite an approximately 18% stock decline. Trading volume was 1.1 times its 20-day average. Business Wire and GlobeNewsWire carried notices about the suits.

How big was the move

The stock closed at $12.85 and fell 2.7% on the day, a move equal to 0.7 times a typical daily move for this stock. Over the last five sessions the stock fell 8.1%, while the S&P 500 fell 1.1% over the same period. The Basic Materials sector median fell 1.5% on the day, so the stock’s performance was 1.2 percentage points worse than the sector median. Chemours has a beta of 1.63, indicating the stock tends to move more than the market. With a market value of $2.05 billion, the company sits toward the smaller end of its sector.

The technical picture

The stock traded well below its key averages: 8.0% below its 20-day moving average, 13.1% below its 50-day moving average and 30.2% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend. The Relative Strength Index (14 days) is 29, below 30, a level often called oversold. Shares are 55.2% below their 52-week high, and have fallen 12.5% over one month and 25.9% over three months. Volatility is 57% annualized over 60 days, higher than 60% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $5.80 billion, a decline of 1.4% from a year earlier. Diluted earnings per share was $-1.99. Gross margin was 15.3% compared with 18.3% a year earlier, and operating margin was 5.2% versus 5.9% a year earlier. Free-cash-flow margin was 2.2% and return on invested capital was 5.7%. Share count increased by 0.8% over one year.

On valuation metrics the stock trades at 12.9 times expected earnings on a price to forward earnings basis, with a free-cash-flow yield of 6.1%. Those measures point to a moderate yield for investors focused on cash generation, though margins and returns indicate pressure on profitability. PromtFinance scores place the company toward the lower end of its sector on growth, quality and stability, with Value at 41 (Weak), Growth at 11 (Very weak), Quality at 20 (Very weak) and Stability at 12 (Very weak); Revisions scored 49 (Neutral).

Earnings and analyst expectations

Chemours last reported on August 4, 2026, posting earnings per share of $0.42 against $0.49 expected, 14.1% below estimates. The company has zero consecutive quarters beating estimates. The average surprise over the last four reports is 31.4% above estimates, and the typical two-day reaction after recent reports was that the stock rose 3.0%. The next report is scheduled for November 5, 2026.

Analysts’ consensus price target is $21.50, which is 67.3% above the closing price, based on 20 analysts. Forty percent of those ratings were Buy or higher, and the consensus rating was Hold. That gap between the consensus target and the current price reflects a divergence between expectations and recent results and price action.

What to watch

• November 5, 2026: next scheduled earnings report.
• December 7, 2026: deadline for lead plaintiff motions in the announced securities class action lawsuits.
• August 4, 2026: last report where EPS was $0.42 versus $0.49 expected, 14.1% below estimates.
• The stock’s Relative Strength Index (14 days) at 29 and its positions relative to the 20-day, 50-day and 200-day averages.